A new study has found that Mounjaro and Zepbound can help with weight loss even in individuals not diagnosed with diabetes.
The findings were published in Diabetes & Metabolism. They examined whether GLP-1 drugs containing tripeptide were effective for weight loss in people without a diabetes diagnosis.
In recent years, the use of GLP-1 class medications as obesity treatments has surged. Notably, drugs like Mounjaro and Ozempic, initially approved in the U.S. as diabetes treatments, have been widely used for weight loss.
In November 2023, the U.S. Food and Drug Administration (FDA) approved the GLP-1 drug Zepbound for chronic weight management in adults who are obese or overweight and have at least one weight-related health condition.
Zepbound and Mounjaro both contain tirzepatide as the active ingredient and are manufactured by Eli Lilly.
Researchers analyzed medical data from 4,100 adults without a diabetes diagnosis using a comprehensive healthcare research database to investigate the weight loss effects of tirzepatide. Eli Lilly sponsored the study.
The results showed that participants lost an average of 13% of their body weight over six months. Additionally, 73.8% of participants continued using tirzepatide for more than six months—a higher continuation rate compared to previous studies.
At the start of the study, 32% of participants had a body mass index (BMI) of 40 or higher, classifying them as severely obese. Meanwhile, 74% had at least one obesity-related complication, and 51% had two or more. The most common complication was dyslipidemia, followed by hypertension, with anxiety disorders being the third most common.
Based on these findings, the researchers concluded that tirzepatide is effective for weight loss even in individuals not diagnosed with diabetes.
Most Commented